Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
03:19 EDT 20 Aug 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
ABBOTT PARK, Ill., Aug. 20, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the XIENCE Xpedition™ Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease. The co...
Other Sources for this Article
More From BioPortfolio on "Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
